ARTICLE | Clinical News
Zybrestat: Final Ph II Study OX4218 data
January 27, 2017 9:08 PM UTC
Final data from the open-label, U.S. Phase II Study OX4218 in 18 patients with well-differentiated, low-to-intermediate-grade, unresectable, recurrent or metastatic PNETs or GI-NETs showed that 60 mg/...
BCIQ Company Profiles
BCIQ Target Profiles